Cessatech

Rethinking Child Treatments - developing evidence-based treatments - specifically for Children

[Cessatech @cessatech]

@sneakview Good question: We believe ‘the savings’ will be around 50% on time and 25% on costs - so rather significant

[Cessatech @cessatech]

Thanks to an amazing effort by the team and the study investigators, we will soon initiate the final safety study 0201 of CT001 – and with less patients than originally planned!
#RethinkingChildTreatments
https://t.co/nrsseEEwWb

[Cessatech @cessatech]

Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001

A fantastic milestone for the company, thanks to everyone involved !
https://t.co/n0ig9k8DNr

[Cessatech @cessatech]

Cessatech announces agreement with the EMA for its second asset CT002 for medical procedural sedation in children...
https://t.co/bBXU3HJWmr

[Cessatech @cessatech]

Cessatech announces agreement with the EMA for its second asset CT002 for medical procedural sedation in children...
Extremely proud on behalf of our team, to share today's big news! Thanks for sharing
https://t.co/bBXU3HJWmr

[Cessatech @cessatech]

An update to the great progress we continue to make....thanks for reading and sharing!
https://t.co/rUlPoz9IEp

[Cessatech @cessatech]

Today we released the Q2-2023 Report.
We are still a very young company, and continue to make great progress - thanks to an amazing team!
https://t.co/SPqHsm0XMS

[Cessatech @cessatech]

Cessatech and Ventis Pharma US partnership for CT001 - We are really looking forward to the collaboration with Ventis Pharma and CEO Tim Patrick - a great company with excellent commercialization skills - a perfect fit for Cessatech. We are truly excited about this opportunity…

[Cessatech @cessatech]

Cessatech and Ventis Pharma announce US partnership for CT001 - thanks to a great effort by the team!
https://t.co/WpDZ5KQMWX

[Cessatech @cessatech]

Thanks for the many questions for our Q1 Q&A session, please see the replies -
Thanks for supporting us!
https://t.co/aUhzP3g7vh

[Cessatech @cessatech]

The Q1 Report is out - looking forward to an exiting year!
Please submit questions to our Q1-Release Q&A session to [email protected], which will be released Tuesday 16 May afternoon..
Thanks for sharing...
https://t.co/KA91dLRQFV

[Cessatech @cessatech]

Our April business update - including the business strategy
Thanks for sharing....
https://t.co/DJAY8WSUjR

[Cessatech @cessatech]

A recent study showed that repurposed drugs had a success rate of 30% compared to 10% for new drugs.
CT001 is an example of repurposing.
Some very well-known examples of repurposing drugs are sildenafil (Viagra) and thalidomide.
https://t.co/kjysQykGqw

[Cessatech @cessatech]

We are pivotal-stage biotech company with a unique focus on children's medicine...

[Cessatech @cessatech]

The Annual Report 2022 has been released; on to a really good track and very excited about the future!
Thanks to a great effort by the team!
https://t.co/JiUCGLU0Uo

[Cessatech @cessatech]

A nationwide survey using national hospital purchase data - Overall, off-label medication was widespread covering virtually all ATC groups and no ATC group had an off-label level lower than 50%...
https://t.co/eQOdV0kwKu

[Cessatech @cessatech]

Welcome to 2023 and our January business update...
https://t.co/kippoCilqg

[Cessatech @cessatech]

Thanks to the team for a great efforts!
https://t.co/yic8u0P7Vu

[Cessatech @cessatech]

Happy that we today completed our successful capital raise through a rights issue - thanks for your support!
https://t.co/RN80ouNcOW

[Cessatech @cessatech]

Please support our ongoing Rights Issue.
Timing is everything, why we have launched a Rights Issue when funding is not critical. We have progressed on all our clinical activities and 2023 will be a very exciting year with pivotal data. Last day 7 Nov
https://t.co/79PeKsYqfd